Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetic susceptibility testing and prophylactic oophorectomy.

A Berchuck1, M E Carney, P A Futreal

  • 1Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA.

European Journal of Obstetrics, Gynecology, and Reproductive Biology
|April 17, 1999
PubMed
Summary

Hereditary ovarian cancer risk is linked to BRCA1/BRCA2 mutations. Prophylactic oophorectomy benefits require more study, prompting interest in chemoprevention and early detection for mutation carriers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic gene expression signature for high-grade serous ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.

Gynecologic oncology·2020
Same author

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Science (New York, N.Y.)·2017
Same author

LIFETIME RISK OF OVARIAN CANCER BASED ON ENDOMETRIOSIS AND OTHER RISK FACTORS: IGCS-0014 06. Ovarian Cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2015
Same author

Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC).

Journal of internal medicine·2012
Same author

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.

The New England journal of medicine·2011

Area of Science:

  • Oncology
  • Genetics
  • Preventive Medicine

Background:

  • Approximately 10% of ovarian cancer cases have a hereditary basis, with family history being a significant risk factor.
  • Identification of BRCA1 and BRCA2 genes allows for targeted risk assessment in families with hereditary ovarian cancer.
  • Prophylactic oophorectomy has been considered for high-risk individuals, but its efficacy in mutation carriers is under investigation.

Purpose of the Study:

  • To evaluate the proven benefits and uncertainties surrounding prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers.
  • To explore the variable penetrance of hereditary ovarian cancer and the factors influencing risk.
  • To assess the occurrence of peritoneal papillary serous carcinoma after oophorectomy and its impact on the procedure's value.

Main Methods:

Related Experiment Videos

  • Review of existing studies on hereditary ovarian cancer risk and prophylactic oophorectomy outcomes.
  • Analysis of reported lifetime risks of ovarian cancer in BRCA1/BRCA2 mutation carriers.
  • Examination of data on the incidence of secondary peritoneal cancers post-oophorectomy.

Main Results:

  • Lifetime ovarian cancer risk in mutation carriers is lower than previously estimated (15-30% vs. 60%).
  • Uncertainty exists regarding the net benefit of prophylactic oophorectomy due to these revised risk estimates and the occurrence of other cancers.
  • The genetic and environmental factors contributing to variable penetrance require further elucidation.

Conclusions:

  • The definitive value of prophylactic oophorectomy for hereditary ovarian cancer requires further research.
  • Chemoprevention and early detection strategies are important considerations for managing ovarian cancer risk in mutation carriers.
  • Improved understanding of penetrance variability is crucial for accurate risk counseling in hereditary cancer syndromes.